It is possible that resistance to the tumour suppressive actions of activin in breast cancer is linked to the levels of secretion of activin neutralizing molecules such as follistatin, as well as a concurrent decrease in expression of activin type II receptors. The gene discussed is INHBE; the disease is neoplasm.